PA-RQM+
RQM+, a leading global MedTech service provider (CRO), today announced leadership appointments for Ronnie Mahofski and Kevin Rowland, both to Executive Vice President and General Manager. Mr. Mahofski will be leading the companies Consulting Services and Fern.ai business units. Mr. Rowland will lead Jordi Labs, an RQM+ company.
“These strategic appointments reflect RQM+'s dedication to returning to the fundamentals that have made us pioneers in the industry. We are confident that Ronnie and Kevin's leadership will further our mission of bringing innovative, safe, and effective medical technology to the patients who need it,” John Potthoff, chief executive officer.
In his expanded role, Mahofski will oversee the regulatory and quality consulting services and the corresponding business development team, as well as tech enablement efforts with Fern.ai. Ronnie joined the RQM+ team in 2015, excelling in key roles within Business Development and serving as Head of Mergers and Acquisitions.
Kevin Rowland has been an integral part of Jordi Labs for nearly 15 years, serving as team leader for the GCMS and LCMS groups, as well as Laboratory Manager and Director of R&D. His expertise includes the interpretation of high-resolution accurate mass MS data for identifying non-target, unknown compounds. In his new role, Kevin provides exceptional service to Jordi Labs' customers and ensures the safety of products for patients in need.
About RQM+
RQM+ is a leading MedTech service provider offering consulting, clinical trial, lab, and reimbursement services, as well as technology solutions to support the entire product lifecycle.
About Jordi Labs, an RQM+ Company
Jordi Labs, an RQM+ Company, provides the highest quality contract analytical services to some of the world’s leading consumer products, polymers, pharmaceutical and medical device manufacturers. Our team of PhD analytical chemists specialize in chemical identification. One of core competencies is Extractables & Leachables testing.
About Fern.ai
Fern.ai, an RQM+ company is a life sciences-focused AI / ML platform to empower clients to seamlessly manage compliance requirements and efficiently navigating the dynamic regulatory landscape. Fern.ai is the only comprehensive platform designed to enhance the entire MedTech lifecycle to deliver quality, speed to market, and compliance from concept to commercialization.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827222171/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Leading the Next Generation of Delicious, Natural and Nutritious Food: Upfield Renamed as Flora Food Group17.9.2024 16:00:00 CEST | Press release
Upfield Group B.V., global branded food champion, announces today that it has changed its name to Flora Food Group B.V. The name change is a substantial step in the company's evolution and follows a performance-driven transformation on multiple levels across the entire company. The new name reflects Flora Food Group’s evolved purpose of delivering the next generation of delicious, natural, and nutritious food that is more affordable and more sustainable than its dairy equivalents. Capitalizing on four global megatrends (population growth, demand for dairy-alternative solutions, animal welfare concerns, and environmental regulations), Flora Food Group leads the change with products that address these trends across four growing categories - butter and spreads, creams, liquids, and cheese - offering consumers a compelling choice. Leveraging its 150+ years of heritage and in-depth R&D expertise, Flora Food Group will seek to drive further conversion in butter, creams, liquids, and cheese,
Vectura Fertin Pharma, Inc., a Subsidiary of Philip Morris International, Announces Agreement for Sale of Vectura Group to Molex17.9.2024 15:04:00 CEST | Press release
Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PMI) (NYSE: PM), today announces the sale of its subsidiary Vectura Group Ltd. (Vectura) to Molex Asia Holdings Ltd., and the establishment of master service agreements to develop Vectura Fertin Pharma’s inhaled therapeutics proprietary pipeline. Vectura will be operated by Phillips Medisize, a Molex company. The sale includes upfront cash consideration of GBP 150 million, subject to customary purchase price adjustments, and potential deferred payments of up to GBP 148 million. The transaction is subject to customary closing conditions, including regulatory approval. “In line with our ambitions, Vectura has enabled us to develop a proprietary pipeline of inhaled therapeutics, and we remain committed to driving innovation in this space over the long-term,” said Jacek Olczak, PMI Chief Executive Officer. PMI’s 2021 acquisition of Vectura has been instrumental in kick-starting Vectura Fertin Pharma’s developmen
Koch Ag & Energy Solutions Selects Cognite to Create Transformative Change in Operations Through Data Discovery & Contextualization17.9.2024 15:00:00 CEST | Press release
Cognite’s Industrial Data Platform Cognite Data Fusion® to serve as a data modeling accelerator using Generative AI to scale across all assets Cognite, the Data and AI authority for industry, and Koch Ag & Energy Solutions (KAES), a global provider of solutions for the agriculture, energy, and chemical markets, today announced a collaboration focusing on leveraging Cognite Data Fusion® to accelerate their digital transformation journey. This collaboration will result in agile data-driven execution in maintenance strategy, turnaround execution, and general efficiency gains across all plants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240823846729/en/ Together, KAES and Cognite will deploy Cognite Data Fusion and co-innovate on custom, Generative AI solutions to accelerate KAES’s data journey, creating new ways of work in operations. Cognite Data Fusion will provide one foundation for operational data, which will be contex
Percona Redefines Cloud-Native Database Management with Percona Everest: the World's First Open Source Public DBaaS Alternative17.9.2024 15:00:00 CEST | Press release
Now generally available, the open source cloud-native database platform enables automated provisioning and management of multiple databases across environments, all within a single, intuitive user interface Percona, a global leader in enterprise-grade open source database software and services, today announced that its groundbreaking new database platform, Percona Everest, is now generally available to the public. Percona Everest is an open source, cloud-native database platform designed to deliver similar core capabilities and conveniences provided by database-as-a-service (DBaaS) offerings but without the burden of vendor lock-in and associated challenges. Percona Everest facilitates the work of developers, QA engineers, DevOps engineers, database administrators, and anyone who could benefit from self-serve deployment and management of MySQL, PostgreSQL and MongoDB on Kubernetes. Percona Everest simplifies database management and enables database deployment standardization across mul
Orbis Medicines and Vivtex Form Research & Exclusive Licensing Collaboration to Support Orbis Development of Next-Generation Orally Dosable ‘nCycles’17.9.2024 14:00:00 CEST | Press release
Orbis’ platform first to systematically explore the macrocycle chemical space Collaboration will unite Vivtex’s best-in-class oral bioavailability screening with Orbis’ leading platform for the discovery and development of oral macrocycles Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a research collaboration and option to an exclusive license with Vivtex, a biotech company aiming to transform the development of oral biologic therapies for major diseases. The collaboration will enable Orbis to utilize Vivtex’s GI-ORIS™ platform for gut permeability screening to evaluate the oral bioavailability of Orbis’ portfolio of next-generation macrocycle drugs it calls ‘nCycles’. “This collaboration extends our ability to design for oral bioavailability into later stages of preclinical development with Vivtex’s extensively validated ex vivo porcine gut model, which is highly informative for human gut interactions. Our goal is faster development of the highest qualit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom